FindTrial
Sign In

Synergistic effect of Arsenic Trioxide on TACE in patients with unresectable HCC

Synergistic effect of Arsenic Trioxide on Transarterial Chemoembolization inpatients with unresectable Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009903
Enrollment
Unknown
Registered
2016-11-17
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Control group:TACE(5-FU 1000mg/m2,DDP 85mg/m2,MMC 6mg/m2), every four weeks
Combination group:TACE(5-FU 1000mg/m2,DDP 85mg/m2,MMC 6mg/m2)+ATO 10mg/d i.v for 7 days, every four weeks

Sponsors

The Second Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The HCC was diagnosed by histopathology; aged less than 75 years, Karnofsky performance score =70; 2. no indication for resection; no previous systemic or local treatment; liver function of Child–Pugh A–B; no portal vein thrombosis or extrahepatic metastasis; no refractory ascites or renal failure; and written informed consent obtained.

Exclusion criteria

Exclusion criteria: Any life-threatening complication or toxicity; allergic reaction to chemotherapy agent or ATO; Liver function Child-pugh C.

Design outcomes

Primary

MeasureTime frame
overall survival probability;disease-free survival probability;—

Secondary

MeasureTime frame
complication and toxicity;—

Countries

China

Contacts

Public ContactJianping Zhang

The Second Affiliated Hospital of Nanjing Medical University

zhang_jp64@aliyun.com+86 18951762705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026